Get the newest information from the Immunization Program right in your inbox!
Sign up
Trouble logging in? Forgot password? We can help!
215-685-6784
215-238-6944
Complete the online reporting agreement form
Or fill out the
then email it to
vaxreporting@phila.gov
or fax to the contact above.
Complete in addition to the reporting agreement form to onboard more than 2 clinics.
Need help? Review the FAQ
Lunch & Learn: Injection Safety Best Practices Join us for an informative, virtual session on Friday, February 2, 2024 from 12 to 1 p.m. This session is for outpatient providers. The Immunization Program is partnering with the Healthcare Associated Infections/Antimicrobial Resistance (HAI/AR) Program within the Division of Disease Control for this...
COVID-19 Vaccine Returns Unopened vaccines should be returned when: The manufacturer expiration date has passed. The vaccines are no longer viable due to out-of-range temperatures. The vaccine has passed its beyond-use-date (BUD). When returning COVID-19 vaccines that have passed their beyond-use-date,remember to select Other as the return reason and include...
Mpox Vaccine: MLK Day Reminder The City of Philadelphia is closed on January 15, 2024 in observance of Martin Luther King Jr. Day. Be sure to submit your mpox vaccine requests by Tuesday, January 16 at 5 p.m. to account for the holiday. Normal deliveries resume...
Catch Up Pediatric Patients: MMR Vaccine There is a measles cluster in Philadelphia that started with an infant and spread to unvaccinated individuals. It has resulted in now 7 confirmed cases of measles among Philadelphia residents and an index case in Delaware county.To prevent further spread, review your...
New Beyond Use Date (BUD) Labels to Order New Beyond Use Date (BUD) labels are available for order. BUD labels can support your practice in ensuring vaccine is not used past expiration. These labels replace previous BUD labels intended for use with COVID-19 vaccine, and can...
Vaccine Product Available Through VFC: Abrysvo Abrysvo is a maternal RSV vaccine available through the Vaccines for Children (VFC) program. RSV is surging and the pediatric infant immunization Beyfortus supply is severely limited. Abrysvo will play an important role in protecting infants against severe RSV disease this season. Most...
Administration Errors: RSV for Infants On November 30, CDC alerted immunization programs that they have received reports of infants being mistakenly administered RSV vaccines intended for adults. Infants should only receive the RSV preventive antibody, nirsevimab (Beyfortus, Sanofi).RSV vaccines (Arexvy by GSK and Abrysvo by Pfizer) are...
Holiday Season Storage and Handling Reminder Ensure your vaccines stay properly monitored over the holiday season! The Digital Data Loggers (DDLs) provided by PDPH have limited storage space and stop recording temperatures when full. If you are using one of these DDLs, please download your DDL files before...
Deauthorized COVID-19 Products As a reminder, only the approved 2023 - 2024 COVID-19 products listed below may be administered at this time: Authorized 2023 - 2024 ProductsFormulation: Monovalent XBB.1.5 Pfizer 12+: NDC 00069-2362-10 Pfizer 5-11: NDC 59267-4331-02 Pfizer 6mo-4yrs: NDC 59267-4315-02 Moderna 12+: NDC 8077-0102-95 Moderna 6mo-11yrs: NDC 8077-0287-92 Novavax 12+: NDC 80631-0105-02 Previously...
Mpox Vaccine Deliveries Paused for Thanksgiving Mpox vaccine deliveries will be paused during the week of Thanksgiving, November 20-24, 2023. Ordering will remain open this week until Wednesday, November 15 by 5:00 PM. The last delivery for mpox vaccine will be on Thursday, November 16. Remember to submit...
Nirsevimab (Beyfortus) Updates Due to the unprecedented demand for nirsevimab, supply of this product is extremely limited through both the Vaccines for Children (VFC) program and the private market. Below is an update on available supply and tips on how to prioritize use of available doses....
Pneumococcal Vaccination for Asthmatic Pediatric Patients This blog post is part of a series highlighting important changes in the 2024 ACIP immunization schedules. This series is written alongside newly onboarded Immunization Program Medical Specialist, Dr. Mayssa Abuali. Dr. Abuali is board certified in general pediatrics, pediatric infectious...
Dosing of Moderna COVID-19 Vaccine (2023-2024 Formula) FDA released important information to ensure correct administration of the Moderna COVID-19 vaccine (2023-2024 formula) for individuals 6 months through 11 years. The announcement states that providers who administer Moderna COVID-19 vaccine (2023-2024 formula) to individuals ages 6 months through 11...
Supply Updates and Borrowing VFC Doses The nirsevimab supply shortage continues to evolve and is not expected to resolve soon. Review this CDC advisory with updates about nirsevimab supply and recommendations to prioritize the use of the limited supply of this product. With these limitations, the Immunization Program wants...
Nirsevimab (Beyfortus) and COVID-19 Updates Nirsevimab Due to high demand and limited supply cited by the CDC, nirsevimab (Beyfortus) ordering through VFC has been put on hold as of October 17, 2023. The CDC is working with Sanofi to secure a supply of this immunization within the...
2023-2024 Novavax Now Available to Order Novavax COVID-19 vaccine, adjuvanted (2023-2024 formula) is now available to order. 2023-2024Novavax is authorized for individuals 12 years and older. This product package contains two multi dose vials each containing five doses. The NDC for this product is NDC # 80631-0105-02. It can...
Mpox Vaccine: Indigenous Peoples' Day Schedule The City of Philadelphia will be closed on Monday, October 9th in observance of Indigenous Peoples' Day. Mpox orders are due by 5pm on Tuesday, October 10th during this week. Deliveries will continue as normal. Order Mpox Vaccine ...
Beyfortus (nirsevimab) Now Available Through VFC On July 17, 2023, FDA licensed AstraZeneca and Sanofi’s Beyfortus (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD). On August 3, the ACIP voted unanimously to recommend nirsevimab for use in infants during the RSV...